|
Bridgebio Pharma Inc (NASDAQ: BBIO) |
|
Bridgebio Pharma Inc
BBIO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bridgebio Pharma Inc 's sales fell
by -33.22 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3153
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Bridgebio Pharma Inc net loss decreased from $-179 millions, to $-164 millions in III. Quarter 2024,
• More on BBIO's Growth
|
|
Bridgebio Pharma Inc realized a net loss in trailing twelve months.
Bridgebio Pharma Inc realized cash reduction of $ -0.62 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 27.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on BBIO's Valuation
|
|
|
|
|
Bridgebio Pharma Inc realized net loss in trailing twelve months.
Bridgebio Pharma Inc realized cash outflow of $ -0.62per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 27.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on BBIO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com